ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Adalimumab"

  • Abstract Number: L20 • 2019 ACR/ARP Annual Meeting

    A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks

    Josef Smolen1, Peter Nash 2, Hasan Tahir 3, Hendrik Schulze-Koops 4, Lingnan Li 5, Maja Hojnik 6, Amanda Gellett 5, Soyi Liu-Leage 7, Sreekumar Pillai 7 and Philip J. Mease 8, 1Medical University of Vienna, Vienna, Austria, 2Griffith University, Brisbane, Queensland, Australia, 3Royal Free London NHS Trust, London, United Kingdom, 4Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, 5Eli Lilly and Company, Indianapolis, Indiana, 6Eli Lilly and Company, Indianapolis, IN, 7Eli Lilly and Company, Indianapolis, 8Swedish Medical Center and University of Washington, Seattle, Washington

    Background/Purpose: Multiple biologic DMARDs (bDMARDs) are available for treatment of PsA, but there are few direct comparisons of their efficacy and safety. Furthermore, efficacy of…
  • Abstract Number: 503 • 2019 ACR/ARP Annual Meeting

    A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects

    Edward Keystone1, Daniel Furst 2, Malcolm Boyce 3, Frans van den Berg 3, SangJoon Lee 4, SungHyun Kim 4, YunJu Bae 4, GoEun Yang 4, JuHeon Koo 4, EunJin Choi 4 and Jonathan Kay 5, 1Mount Sinai Hospital, Toronto, Canada, 2University of California, Los Angeles, CA, 3Hammersmith Medicines Research, London, United Kingdom, 4Celltrion Inc., Incheon, Republic of Korea, 5UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: CT-P17 is a recombinant humanized monoclonal antibody that was developed as a biosimilar to the reference product, adalimumab. This was a first in human…
  • Abstract Number: 1407 • 2019 ACR/ARP Annual Meeting

    Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis

    Peter Taylor1, Janet Pope 2, Kei Ikeda 3, Xiang Zhang 4, Bochao Jia 4, Hong Zhang 5, Amanda Quebe 4, Yun-Fei Chen 4, Carol Gaich 4, Thorsten Holzkaemper 4, Anabela Cardoso 4 and Anthony Sebba 6, 1University of Oxford, Oxford, United Kingdom, 2Western University, London, ON, Canada, 3Chiba University Hospital, Chiba, Japan, 4Eli Lilly and Company, Indianapolis, IN, 5TechData Services, King of Prussia, PA, 6University of South Florida, Palm Harbor, FL

    Background/Purpose: In Phase 3 trial, RA-BEAM, baricitinib (BARI), a JAK1/JAK2 inhibitor, was associated with significant clinical improvements vs. placebo (PBO) and adalimumab (ADA) in RA…
  • Abstract Number: 1424 • 2019 ACR/ARP Annual Meeting

    The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial

    Jane Buckner1, Vivian Bykerk 2, V. Michael Holers 3, S. Louis Bridges 4, William Rigby 5, Sheng Gao 6, Marleen Nys 7 and Neelanjana Ray 8, 1Benaroya Research Institute, Seattle, WA, 2Hospital for Special Surgery, New York City, NY, 3University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, 4University of Alabama at Birmingham, Birmingham, 5Dartmouth-Hitchcock Medical Center, Lebanon, 6Bristol-Myers Squibb, Princeton, NJ, 7Bristol-Myers Squibb, Braine L’Alleud, Belgium, 8Bristol-Myers Squibb, Princeton

    Background/Purpose: Mechanistic differences between biologic DMARDs are poorly understood. Exploring these mechanisms includes assessing the role of HLA-DRB1 alleles containing the shared epitope (SE), which…
  • Abstract Number: 1880 • 2019 ACR/ARP Annual Meeting

    Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials

    Janet Pope1, Yvonne Lee 2, Jeffrey Curtis 3, Daojun Mo 4, Terence Rooney 4, Li Xie 4, Christina Dickson 4, Douglas Schlichting 4, Amanda Quebe 4, Anabela Cardoso 4, Lee Simon 5 and Peter Taylor 6, 1Western University, London, ON, Canada, 2Northwestern University Feinberg School of Medicine, Chicago, 3University of Alabama at Birmingham, Birmingham, AL, 4Eli Lilly and Company, Indianapolis, IN, 5SDG LLC, Cambridge, MA, 6University of Oxford, Oxford, United Kingdom

    Background/Purpose: Opioid use in RA patients has increased over the past 2 decades in the US. Little is known about the combined effects of opioids…
  • Abstract Number: 2699 • 2019 ACR/ARP Annual Meeting

    Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab

    Najima Mwase 1, Theresa Hennard 2, Joseph McDonald 3, Amy Cassedy 4, Onengiya Harry 3 and Sheila Angeles-Han5, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, 3Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, 4Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, 5Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati

    Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is the most common extra-articular manifestation of JIA, leading to ocular complications and blindness when not adequately treated. First…
  • Abstract Number: 2907 • 2019 ACR/ARP Annual Meeting

    Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response

    Roy Fleischmann1, Mark Genovese 2, Ricardo Blanco 3, Stephen Hall 4, Glen Thomson 5, Filip Van den Bosch 6, Cristiano A. Zerbini 7, Jose Jeffrey Enejosa 8, Yihan Li 9, Ryan DeMasi 9 and In-Ho Song 8, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2Stanford University, Stanford, CA, 3Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, 4Monash University and Emeritus Research, Melbourne, Australia, 5CIADS Research, Winnipeg, Canada, 6Ghent University Hospital, Ghent, Belgium, 7Centro Paulista de Investigação Clinica, São Paulo, Brazil, 8AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, 9AbbVie Inc., North Chicago, IL

    Background/Purpose: The goal of RA treatment is to achieve clinical remission or, at minimum, low disease activity (LDA). Modification of initial csDMARD therapy with the…
  • Abstract Number: 1638 • 2018 ACR/ARHP Annual Meeting

    Impact of Extra-Articular Manifestations on Patient-Reported Outcomes in Ankylosing Spondylitis and Psoriatic Arthritis: Interim Results from the Complete Studies

    Louis Bessette1, Majed Khraishi2,3, Brandusa Florica4, Yatish Setty5, Michelle Teo6 and Valencia P. Remple7, 1Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, 2Memorial University of Newfoundland, St. John's, NF, Canada, 3Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, 4University of Toronto, Toronto, ON, Canada, 5Grey Bruce Health Services, Owen Sound, ON, Canada, 6University of British Columbia, Penticton, BC, Canada, 7AbbVie Corporation, Montreal, QC, Canada

    Background/Purpose: Extra-articular manifestations (EAMs) in rheumatic diseases have been previously found to negatively impact health outcomes including quality of life and work capacity. Even though…
  • Abstract Number: 2560 • 2018 ACR/ARHP Annual Meeting

    Efficacy of Guselkumab in Psoriasis Patients with Self-Reported Psoriatic Arthritis with Involvement of the Scalp, Nails, Hands, and Feet: A Pooled Analysis from 2 Pivotal Phase 3 Psoriasis Studies

    Ana-Maria Orbai1, Soumya D Chakravarty2, Yin You3, Shelly Kafka4, Chetan S Karyekar4 and Joseph F. Merola5, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Janssen Scientific Affairs, LLC/Drexel U School of Medicine, Horsham/Phila, PA, 3Janssen Research & Development, LLC, Spring House, PA, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA

       Background/Purpose: VOYAGE 1 & 2 were the pivotal Ph3 GUS trials for plaque PsO.1,2 Here we compare efficacy of GUS vs PBO & adalimumab (ADA)…
  • Abstract Number: 1773 • 2018 ACR/ARHP Annual Meeting

    Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis Due to Behçet’s Disease. National Multicenter Study of 177 Cases

    Belén Atienza-Mateo1, José Luis Martín-Varillas1, Vanesa Calvo-Río2, Rosalía Demetrio-Pablo3, Emma Beltrán4, Marina Mesquida5, Alfredo Adan5, Juan Sánchez Bursón Sr.6, M. Victoria Hernández7, Marisa Hernández8, Elia Valls-Pascual9, L. Martinez-Costa9, Agusti Sellas-Fernandez10, Miguel Cordero-Coma11, Manuel Díaz-Llopis12, Roberto Gallego12, Jose L. García Serrano13, Norberto Ortego Centeno14, Angel Garcia-Aparicio15, Olga Maiz-Alonso16, Ana Blanco17, Cruz Fernandez-Espartero18, Vega Jovaní19, Diana Peiteado20, Elena Aurrecoechea21, Amalia Sanchez-Andrade22, Enrique Minguez23, Carmen Carrasco-Cubero24, Alejandro Olivé-Marqués25, Esteban Rubio-Romero26, Francisco J. Toyos Sáenz de Miera27, David Diaz-Valle28, Joan Miquel Nolla29, Marcelino Revenga Martínez30, Santos Castañeda31, Jose M Herreras32, Alejandro Fonollosa33, Ignacio Torre-Salaberri34, Esperanza Pato Cour35, Juan Cruz36, Carlos Férnandez Cid37, Miriam García-Arias38, Miguel Angel Caracuel-Ruiz39, Carlos Alberto Montilla-Morales40, Antonio Atanes41, Félix Francisco42, Santos Insua43, Senen González-Suárez44, Fernando Gamero45, Luis Francisco Linares46, Fredeswinda I. Romero-Bueno47, Raquel Almodóvar González48, Julio Vázquez49, A. Javier García-González50, Oscar Ruiz Moreno51, Fernando Jiménez-Zorzo51, Javier Manero51, Santiago Muñoz Fernandez52, Fred Antón Pages53, Myriam Gandía54, Francisco Javier López Longo55, Enrique Raya Álvarez56, Paz Rodríguez-Cundín57, Diana Prieto Peña2, Monica Calderón Goercke2, Enar Pons1, José Luis Hernández3, Miguel Angel González-Gay1 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, 5Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 6Rheumatology, Hospital de Valme. Sevilla. Spain, Sevilla, Spain, 7Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 8Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, 9Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, 10Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 11Ophthalmology, Hospital de León. Spain, León, Spain, 12Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, 13Ophthalmology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 14Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 15Rheumatology, Hospital de Toledo. Toledo. Spain, Toledo, Spain, 16Hospital Universitario Donostia. San Sebastian. Spain, Donostia, Spain, 17Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, 18Rheumatology, Hospital de Móstoles. Madrid. Spain, Madrid, Spain, 19Rheumatology, Hospital General Universitario de Alicante. Spain, Alicante, Spain, 20Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, 21Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, 22Rheumatology, Hospital Lucus Augusti. Lugo. Spain, Lugo, Spain, 23Ophthalmology, Hospital Clínico de Zaragoza. Spain, Zaragoza, Spain, 24Hospital de Mérida. Spain, Mérida, Spain, 25Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 26Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, 27Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, 28Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, 29Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 30Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, 31Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, 32Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, 33Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, 34Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 35Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 36Rheumatology, Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, 37Ophthalmology, Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, 38Hospital Universitario de la Princesa. Madrid. Spain, Madrid, Spain, 39Rheumatology service, Hospital Universitario Reina Sofía. Córdoba. Spain, Córdoba, Spain, 40Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, 41Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, 42Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, 43Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, 44Rheumatology, Hospital de Cabueñes. Gijón. Spain, Gijón, Spain, 45Rheumatology, Hospital San Pedro Alcántara. Cáceres. Spain, Cáceres, Spain, 46Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, 47Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, 48Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, 49Rheumatology, Hospital de Ferrol. La Coruña. Spain, La Coruña, Spain, 50Rheumatology, Instituto de Investigación Hospital 12 de octubre. Madrid. Spain, Madrid, Spain, 51Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 52Hospital Universitario Infanta Sofía. Madrid. Spain, San Sebastián de los Reyes (Madrid), Spain, 53Rheumatology, Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, 54Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, 55Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 56Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 57Preventive Medicine, Preventive Medicine. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain., Santander, Spain

    Background/Purpose: Uveitis is one of the major causes of disability of Behçet's disease (BD). According to the “Expert panel recommendations” (Ophthalmology. 2014; 121:785-96), anti-TNF therapy…
  • Abstract Number: 2566 • 2018 ACR/ARHP Annual Meeting

    Impact of Guselkumab Versus Placebo and Adalimumab on Patient Reported Outcomes in Patients with and without Psoriatic Arthritis in a Phase 3 Pivotal Psoriasis Study

    Luis Puig1, Chenglong Han2, Ronald Vender3, Michael Song2, Yin You2, Yaung-Kaung Shen2 and Peter Foley4, 1Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona Medical School, Barcelona, Spain, 2Janssen Research & Development, LLC, Spring House, PA, 3McMaster University, Hamilton, ON, Canada, 4University of Melbourne, St. Vincent’s Hospital, Melbourne and Skin & Cancer Foundation Inc., Carlton, Australia

    Background/Purpose: VOYAGE 2 is a phase 3 double-blind, placebo/active comparator-controlled trial comparing guselkumab (GUS) with placebo (PBO) and adalimumab (ADA) in patients (pts) with moderate-to-severe…
  • Abstract Number: 1804 • 2018 ACR/ARHP Annual Meeting

    Optimization Protocol for Adalimumab Treatment in Refractory Uveitis Due to Behçet’s Disease

    José Luis Martín-Varillas1, Belén Atienza-Mateo1, Vanesa Calvo-Río2, Diana Prieto Peña2, Monica Calderón Goercke2, Eva Peña Sainz-Pardo3, Emma Beltrán4, Juan Sánchez Bursón Sr.5, M. Victoria Hernández6, Alfredo Adan7, Marina Mesquida7, Marisa Hernández8, Elia Valls-Pascual9, Lucía Martínez-Costa9, Agusti Sellas-Fernandez10, Miguel Cordero-Coma11, Manuel Díaz-Llopis12, Roberto Gallego12, David Salom12, Norberto Ortego Centeno13, Jose L. García Serrano14, José-Luis Callejas-Rubio15, Jose M Herreras16, Angel Garcia-Aparicio17, Olga Maíz18, Ana Blanco19, Ignacio Torre-Salaberri20, David Diaz-Valle21, Esperanza Pato Cour22, Elena Aurrecoechea23, Miguel A. Caracuel24, Fernando Gamero25, Enrique Minguez26, Carmen Carrasco-Cubero27, Alejandro Olivé-Marqués28, Oscar Ruiz Moreno29, Javier Manero29, Julio Vázquez30, Santiago Muñoz Fernandez31, Myriam Gandía32, Esteban Rubio-Romero33, Francisco Toyos34, Francisco Javier López Longo35, Joan Miquel Nolla36, Marcelino Revenga Martínez37, Javier Loricera3, Rosalía Demetrio-Pablo3, Enar Pons1, José Luis Hernández3, Miguel Angel González-Gay3 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, 5Rheumatology, Hospital de Valme. Sevilla. Spain, Sevilla, Spain, 6Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 7Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 8Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, 9Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, 10Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 11Ophthalmology, Hospital de León. Spain, León, Spain, 12Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, 13Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 14Ophthalmology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 15Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 16Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, 17Rheumatology, Hospital de Toledo. Toledo. Spain, Toledo, Spain, 18Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, 19Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, 20Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 21Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, 22Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 23Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, 24Hospital de Córdoba, Córdoba, Spain., Córdoba, Spain, 25Rheumatology, Hospital San Pedro Alcántara. Cáceres. Spain, Cáceres, Spain, 26Ophthalmology, Hospital Clínico de Zaragoza. Spain, Zaragoza, Spain, 27Hospital de Mérida. Spain, Mérida, Spain, 28Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 29Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 30Rheumatology, Hospital de Ferrol. La Coruña. Spain, La Coruña, Spain, 31Hospital Universitario Infanta Sofía. Madrid. Spain, San Sebastián de los Reyes (Madrid), Spain, 32Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, 33Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, 34Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, 35Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 36Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 37Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain

    Background/Purpose: Uveitis is the most common ocular manifestation in Behçet Disease (BD), which can cause irreversible blindness. Once the efficacy, safety and cost-effectiveness of Adalimumab…
  • Abstract Number: 2569 • 2018 ACR/ARHP Annual Meeting

    Association of Enthesitis with Achievement of Normal Quality of Life and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Adalimumab

    Philip J. Mease1, Filip van Den Bosch2, Uta Kiltz3, Patrick Zueger4, Kun Chen4, Meijing Wu4 and Jaclyn K. Anderson4, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Ghent University, Ghent, Belgium, 3Rheumazentrum Ruhrgebiet, Herne, Germany, 4AbbVie Inc., North Chicago, IL

    Background/Purpose: Enthesitis, a key pathology in non-radiographic axial spondyloarthritis (nr-axSpA), has been difficult to treat with conventional therapies and may take longer to resolve than…
  • Abstract Number: 1936 • 2018 ACR/ARHP Annual Meeting

    A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis

    Piotr Wiland1, Sławomir Jeka2, Eva Dokoupilová3,4, Juan Manuel Miranda Limón5, Julia Jauch-Lembach6, Anjali Thakur6, Halimuniyazi Haliduola6 and Norman B Gaylis7, 1Wrocław Medical University, Wrocław, Poland, 2Collegium Medicum UMK, 2nd University Hospital, Bydgoszcz, Poland, 3MEDICAL PLUS s.r.o., Uherské Hradiště, Czech Republic, 4Faculty of Pharmacy, University of Veterinary and Pharmaceutical sciences, Brno, Czech Republic, 5RM Pharma Specialists, Mexico City, Mexico, 6Hexal AG, Holzkirchen, Germany, 7Arthritis & Rheumatic Disease Specialties, Aventura, FL

    Background/Purpose: GP2017, a proposed adalimumab biosimilar, matched reference adalimumab (refADL) in preclinical and pharmacokinetics studies.1,2 The confirmatory efficacy and safety study in patients with plaque-type…
  • Abstract Number: 2571 • 2018 ACR/ARHP Annual Meeting

    Adalimumab Serum Concentration Fails to Predict Achievement of Sustained Remission or Absence of Flare for Patients with Non-Radiographic Axial Spondyloarthritis

    Nisha Kwantra1, Marina Magrey2, Philip J. Mease3, Joachim Sieper4, Robert B.M. Landewé5, Xin Wang6, Apinya Lertratanakul1, Jaclyn K. Anderson1 and Nael Mostafa1, 1AbbVie Inc., North Chicago, IL, 2Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, 3Swedish Medical Center and University of Washington, Seattle, WA, 4University Clinic Benjamin Franklin, Berlin, Germany, 5Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, 6AbbVie, North Chicago, IL

    Background/Purpose: In patients (pts) with active non-radiographic axial spondyloarthritis (nr-axSpA) in the ABILITY-3 study who achieved sustained remission with adalimumab (ADA), continued ADA therapy was…
  • 1
  • 2
  • 3
  • …
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology